Results 71 to 80 of about 1,083 (163)

[Metformin and malignant neoplasms: a possible mechanism of antitumor action and prospects for use in practice]. [PDF]

Probl Endokrinol (Mosk), 2022
Kuznetsov KO, Safina ER, Gaimakova DV, Frolova YS, Oganesyan IY, Sadertdinova AG, Nazmieva KA, Islamgulov AH, Karimova AR, Galimova AM, Rizvanova EV.   +10 more
europepmc   +1 more source

THE USE OF MULTI-COMPONENT THERAPY IN THE MANAGEMENT OF METABOLIC SYNDROME

Alʹmanah Kliničeskoj Mediciny, 2016
Background: The metabolic syndrome (MS) is a cluster of hormonal and metabolic abnormalities arising from insulin resistance. It is associated with high risk of diabetes and cardiovascular disease.
S. V. Nedogoda, I. N. Barykina, A. S. Salasyuk, V. Yu. Khripaeva, V. O. Smirnova   +4 more
doaj   +1 more source

[Use of metformin in patients with type 2 diabetes and acute myocardial infarction: safety and impact on glycemic control]. [PDF]

Probl Endokrinol (Mosk), 2023
Korotina MA, Pochinka IG, Strongin LG.
europepmc   +1 more source

Основные патогенетические механизмы развития сердечно-сосудистых осложнений у пожилых больных с ХПН и пути их коррекции [PDF]

, 2010
Современные представления о патогенетических механизмах развития сердечно-сосудистых осложнений у пожилых больных, страдающих хронической почечной недостаточностью и способах их коррекцииyesБелгородский государственный ...
Ефремова, О. А., Крутова, М. С.   +1 more
core   +2 more sources

Restoration of adaptive cardioprotection impaired by metabolic syndrome in rats by the PPARα activation

Acta Biomedica Scientifica
Background. It is known that the protective effect of adaptation and conditioning influence is weakened in animals with metabolic syndrome. Metabolic syndrome may be the basis for the failure of cardioprotection in clinical settings.The aim of the study.
N. V. Naryzhnaya, I. A. Derkachev, B. K. Kurbatov, M. A. Sirotina, M. Kilin, L. N. Maslov   +5 more
doaj   +1 more source

[Toxic manifestations of alpelisib in endocrinology. Description of the clinical case]. [PDF]

Probl Endokrinol (Mosk), 2023
Kudaeva LM, Kozhedub EE, Kupryshina VO, Aliyev TZ, Troshina EA.   +4 more
europepmc   +1 more source

Вплив піоглітазону на гемостаз та протеоліз у хворих на гіпертонічну хворобу в поєднанні з цукровим діабетом другого типу [PDF]

, 2013
Обследовано 30 больных на гипертоническую болезнь в сочетании с сахарным диабетом 2-го типа в динамике лечения комбинацией антигипертензивных средств (S-амлодипин и лизиноприл) с метформином или пиоглитазоном.
Білецький, С.В., Казанцева, Т.В., Петринич, О.А.   +2 more
core  

[Semaglutide - effectiveness in weight loss and side effects when used according to studies by SUSTAIN, PIONEER, STEP]. [PDF]

Probl Endokrinol (Mosk), 2023
Shabutdinova OR, Dautov AR, Samkov AA, Kononenko AV, Sargaliev AF, Davletshin AR, Andresova PA, Zarbeeva KR, Torshkhoeva DA, Rakhmonkulov UA, Afanasyev AA.   +10 more
europepmc   +1 more source

Complex correction of erectile and copulative violations at patients with obesity and reproductive function violation [PDF]

, 2013
The study aimed the development and assessment of features of corrective action of a medical complex on a lipid imbalance at patients with obesity. Material and methods.
Kotenko K.V., Slonimskiy В.Yu.
core  

Pharmacogenetic aspects of oral hypoglycemic therapy. Response and failure phenotypes

Медицинский совет, 2015
The research work attempted to answer the question whether an effective personalized glucose-lowering therapy, particularly with metformin, is possible in patients with type 2 diabetes based on single nucleotide polymorphism of the three genes ...
Y. A. Sorokina
doaj   +1 more source